(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/056431 A1

(51) International Patent Classification:
A61K 31/44 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/077364

(22) International Filing Date:
30 September 2022 (30.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/251,536 01 October 2021 (01.10.2021) US
63/357,309 30 June 2022 (30.06.2022) US

(71) Applicant: **NUVALENT, INC.** [US/US]; One Broadway, 14th Floor, Cambridge, MA 02142 (US).


(72) Inventors: **DESHPANDE, Amit, M.**; One Broadway, 14th Floor, Cambridge, MA 02142 (US). **NOCI, Darlene**; One Broadway, 14th Floor, Cambridge, MA 02142 (US). **PELISH, Henry, Efrem**; One Broadway, 14th Floor, Cambridge, MA 02142 (US). **PORTER, James, R.**; One Broadway, 14th Floor, Cambridge, MA 02142 (US). **SOGLIA, John, R.**; One Broadway, 14th Floor, Cambridge, MA 02142 (US). **TANGPEERACHAIKUL, Anupong**; One Broadway, 14th Floor, Cambridge, MA 02142 (US). **TURNER, Christopher, Durant**; One Broadway, 14th Floor, Cambridge, MA 02142 (US). **MEYERS, Michael**; 211 East 43rd Street, #900, New York, NY 10017 (US).

(74) Agent: **YANG, Kunyong** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: METHODS OF TREATING SOLID TUMOR USING HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS



(a) Higher dose levels (DLs) may be explored based on recommendation and approval of the SRC and confirmation from the Sponsor;
(b) Platinum-based chemotherapy ± immunotherapy;
(c) Either crizotinb or entrectinib;
(d) Includes NSCLC who do not qualify for any of the other cohorts.
I-O: Immunotherapy; QD: Once daily; RP2D: Recommended Phase 2 Dose; TKI: Tyrosine Kinase Inhibitor

FIG. 1

(57) **Abstract:** Provided herein are methods of using a heteroaromatic macrocyclic ether compound (e.g., Compound 1), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing solid tumor.

[Continued on next page]

WO 2023/056431 A1

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*